We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice.
- Authors
Jacene, Heather A; Filice, Ross; Kasecamp, Wayne; Wahl, Richard L
- Abstract
We retrospectively evaluated our single-center clinical experience with (90)Y-ibritumomab tiuxetan and (131)I-tositumomab for therapy of refractory non-Hodgkin's lymphoma (NHL). We evaluated the hypothesis that the patient-specific dosing regimen used with (131)I-tositumomab results in less bone marrow toxicity than does the weight-based dosing regimen used with (90)Y-ibritumomab tiuxetan.
- Publication
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2007, Vol 48, Issue 11, p1767
- ISSN
0161-5505
- Publication type
Journal Article
- DOI
10.2967/jnumed.107.043489